scholarly journals Impact of Peritumoral Edema on Overall Survival in Glioblastoma Multiforme

2016 ◽  
Author(s):  
Mustafa KANDAZ
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Peritumoral Edema

The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

2021 ◽  
Author(s):  
Deniz Can Guven ◽  
Melek Seren Aksun ◽  
Ibrahim Yahya Cakir ◽  
Saadettin Kilickap ◽  
Neyran Kertmen
Keyword(s):  
Overall Survival ◽  
Body Composition ◽  
Glioblastoma Multiforme ◽  
Random Effects ◽  
Muscle Thickness ◽  
Pooled Analysis ◽  
Random Effects Model ◽  
Temporal Muscle ◽  
Inverse Variance ◽  
Meta Analyses

Background: The association between obesity and sarcopenia (via temporal muscle thickness) with overall survival (OS) has been evaluated in several glioblastoma multiforme studies, however, the data are inconclusive. Methods: The authors conducted meta-analyses via the generic inverse-variance method with a random-effects model. Results: In the pooled analysis of five studies, including 973 patients, patients with lower temporal muscle thickness had significantly decreased OS (HR: 1.62, 95% CI: 1.16–2.28, p = 0.005). The pooled analysis of five studies, including 2131 patients, demonstrated decreased OS in patients with lower BMI compared with patients with obesity (HR: 1.45, 95% CI: 1.12–1.88, p = 0.005). Conclusion: Readily available body composition parameters could be used for prognosis prediction and to aid in treatment decisions in patients with glioblastoma multiforme.

MRI Radiomic Features of Peritumoral Edema May Predict the Recurrence Sites of Glioblastoma Multiforme

2021 ◽  
Author(s):  
Hao Long ◽  
Ping Zhang ◽  
Yuewei Bi ◽  
Chen Yang ◽  
Manfeng Wu ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Peritumoral Edema ◽  
Recurrence Sites

scholarly journals Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study

2019 ◽  
Vol 11 ◽  
pp. 175883591985395 ◽  
Author(s):  
Elles J. T. M. van der Louw ◽  
Joanne F. Olieman ◽  
Patricia M. L. A. van den Bemt ◽  
Jacoline E. C. Bromberg ◽  
Esther Oomen-de Hoop ◽  
...  
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Ketogenic Diet ◽  
Standard Treatment ◽  
Medium Chain Triglyceride ◽  
High Grade Glioma ◽  
Future Research ◽  
Clinical Trial Registration ◽  
Beneficial Effects ◽  
Neurological Functioning

Background: High-grade glioma cells consume mainly glucose and cannot compensate for glucose restriction. Apoptosis may potentially occur under carbohydrate restriction by a ketogenic diet (KD). We explored the feasibility and safety of KD during standard treatment of chemoradiation in patients with glioblastoma multiforme. Methods: A full liquid KD induced ketosis within 2 weeks before start of chemoradiation. After 6 weeks, the KD was modified with solid foods and medium-chain-triglyceride emulsions and used for an additional 6 weeks while maintaining ketosis. During the total study period (14 weeks), feasibility, safety, coping (both patient and partner), quality of life (QoL), neurological functioning and impairment were measured. Overall survival was analyzed with actuarial estimates. Results: Eleven patients started the study protocol, nine reached ketosis and six (67%) completed the study. Severe adverse effects did not occur. The majority of coping scores ranged from 3 to 6 on a 10-point scale at all timepoints; QoL, neurological functioning, and impairment did not essentially change over time; overall survival ranged between 9.8 and 19.0 months. Conclusion: KD was feasible and safe as an adjuvant to standard chemoradiation treatment of glioblastoma multiforme. A supportive partner and intensive counseling were essential for coping. Future research should identify possible beneficial effects on overall survival. Clinical trial registration: Netherlands Trial Registry: NTR5167 (registration date 29-01-2015), http://www.trialregister.nl/trialreg/index.asp

scholarly journals Low GAS5 Levels as a Predictor of Poor Survival in Patients with Lower-Grade Gliomas

2019 ◽  
Vol 2019 ◽  
pp. 1-15 ◽  
Author(s):  
Yanfang Wang ◽  
Shan Xin ◽  
Kai Zhang ◽  
Run Shi ◽  
Xuanwen Bao
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Translation Initiation ◽  
Noncoding Rna ◽  
Rank Test ◽  
Molecular Characteristics ◽  
Normal Brain ◽  
Lower Grade ◽  
Ribosomal Biogenesis ◽  
Rna Seq

Introduction. Gliomas are infiltrative neoplasms of a highly invasive nature. Different stages of gliomas feature distinct genomic, genetic, and epigenetic changes. The long noncoding RNA Growth Arrest Specific Transcript 5 (GAS5) is an identified tumour suppressor involved in several cancers. However, the underlying roles of the GAS5 gene in lower-grade glioma (LGG) patients are not clear. Methods. Via bioinformatic analysis based on TCGA-LGG and TCGA-GBM data, we explored the mechanisms of GAS5 expression in LGG (grades II and III) and high-grade glioma (glioblastoma multiforme, grade IV). The log-rank test and multivariate Cox analysis were performed to find the association between GAS5 and overall survival (OS) in LGG patients. Weighted gene coexpression network analysis (WGCNA) and RNA-Seq analysis were applied to find the key gene network associated with GAS5. Results. We found that GAS5 expression was downregulated in both LGG and glioblastoma multiforme (GBM) compared with normal brain tissue. Low methylation in the GAS5 promoter region was detected in both LGG and GBM tissues. The amplification type was the predominant type of GAS5 gene alteration in both LGG and GBM. High GAS5 expression was more associated with long overall survival (OS) in LGG patients than in GBM patients. The multivariate survival analysis of GAS5 and clinical and molecular characteristics in LGG patients further confirmed the association between GAS5 and OS in LGG patients. We then developed a nomogram for clinical use. WGCNA and RNA-Seq analysis indicated that ribosomal biogenesis and translation initiation were the predominant events regulated by GAS5 in LGG patients. Conclusion. Taken together, these results demonstrate that GAS5 expression is associated with OS in LGG patients and that its underlying roles involve the regulation of ribosomal biogenesis and translation initiation, which may aid in identifying a new target for the treatment of LGG.

scholarly journals The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme

2008 ◽  
Vol 10 (4) ◽  
pp. 548-552 ◽  
Author(s):  
Michael Linnebank ◽  
Alexander Semmler ◽  
Susanna Moskau ◽  
Yvo Smulders ◽  
Henk Blom ◽  
...  
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Methylenetetrahydrofolate Reductase

Abstract 3575: Dysregulated expression of lncRNAs in glioblastoma multiforme and their association with overall survival

2019 ◽  
Author(s):  
Marek Vecera ◽  
Jan Oppelt ◽  
Lenka Radova ◽  
Radim Lipina ◽  
Stefan Reguli ◽  
...  
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme

Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2076-2076
Author(s):  
M. Khalil ◽  
J. Wulfkuhle ◽  
H. Fillmore ◽  
J. Deng ◽  
L. Liotta ◽  
...  
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Brain Metastases ◽  
Protein Microarrays ◽  
Patient Specific ◽  
Critical Pathway ◽  
Human Glioblastoma ◽  
Pathway Mapping ◽  
Human Glioblastoma Multiforme ◽  
Pathway Activation

2076 Background: Genome scanning analysis of human glioblastoma multiforme (GBM) has suggested that this form of cancer is a protein pathway disease. Since genomic analysis cannot directly predict protein activation, analysis of protein pathway activation is required. With the current focus on targeted translational therapeutic modalities, a functional understanding of the GBM signaling repertoire is critical, and yet largely unknown. Methods: Twelve tumors were included in this study: 10 GBMs (9 primary, 1 recurrent) and two brain metastases (1 breast and 1 lung). Pure tumor cell populations were obtained from fixed frozen tissue sections using Laser Capture Microdissection. Protein pathway mapping was performed using Reverse Phase Protein Microarrays (RPMA) whereby the activation of 85 key signaling proteins was quantitatively measured at once. Unsupervised and supervised analysis was used to explore pathway activation. Results: Unsupervised hierarchical clustering of all tumors in the study set revealed largely patient-specific signaling portraits yet also identified distinct pathway subsets. The two metastatic tumors clustered separately and distinctly from the GBMs. The GBM specimens clustered according to pathway activity. Statistical analysis demonstrated significant correlations between certain phosphorylated endpoints detected and overall survival. Phosphorylation of cofilin (S3) was associated with shorter survival time, while Stat1 (Y701) and Shc (Y317) phosphorylation were both positively correlated with longer overall survival. Conclusions: This study represents the most comprehensive proteomic analysis of human GBM pathway mapping to date. Since certain pathway biomarkers are themselves being targeted by current investigational therapies, the ability to map pathway activation and identify critical pathway biomarkers can lead to targeted therapeutics tailored to each patient's tumor. The ability to segregate short from long-term survivors according to protein pathway activation is promising. [Table: see text]

Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial

2004 ◽  
Vol 22 (9) ◽  
pp. 1583-1588 ◽  
Author(s):  
W. Roa ◽  
P.M.A. Brasher ◽  
G. Bauman ◽  
M. Anthes ◽  
E. Bruera ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Glioblastoma Multiforme ◽  
Older Patients ◽  
Treatment Time ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Wilcoxon Test ◽  
Rank Test ◽  
Survival Times

Purpose To prospectively compare standard radiation therapy (RT) with an abbreviated course of RT in older patients with glioblastoma multiforme (GBM). Patients and Methods One hundred patients with GBM, age 60 years or older, were randomly assigned after surgery to receive either standard RT (60 Gy in 30 fractions over 6 weeks) or a shorter course of RT (40 Gy in 15 fractions over 3 weeks). The primary end point was overall survival. The secondary end points were proportionate survival at 6 months, health-related quality of life (HRQoL), and corticosteroid requirement. HRQoL was assessed using the Karnofsky performance status (KPS) and Functional Assessment of Cancer Therapy-Brain (FACT-Br). Results All patients had died at the time of analysis. Overall survival times measured from randomization were similar at 5.1 months for standard RT versus 5.6 months for the shorter course (log-rank test, P = .57). The survival probabilities at 6 months were also similar at 44.7% for standard RT versus 41.7% for the shorter course (lower-bound 95% CI, −13.7). KPS scores varied markedly but were not significantly different between the two groups (Wilcoxon test, P = .63). Low completion rates of the FACT-Br (45%) precluded meaningful comparisons between the two groups. Of patients completing RT as planned, 49% of patients (standard RT) versus 23% required an increase in posttreatment corticosteroid dosage (χ2 test, P = .02). Conclusion There is no difference in survival between patients receiving standard RT or short-course RT. In view of the similar KPS scores, decreased increment in corticosteroid requirement, and reduced treatment time, the abbreviated course of RT seems to be a reasonable treatment option for older patients with GBM.

Sign in / Sign up

Export Citation Format

Share Document